Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study

摘要

National guidelines support the use of hydroxyurea (HU) in high-risk patients with polycythemia vera (PV). In this study, we investigated HU treatment patterns in patients with PV. Of patients who received HU for >= 3 months, 32.3% had dose adjustments, 23.7% had dose interruptions, and 18.6% discontinued HU. These results emphasize the need for active management of patients with PV.